Emerging approaches to target tumor metabolism

Current Opinion in Pharmacology

Volumn 17, Issue 1, 2014, Pages 22-29

  Ross, Sarah J ^a   Critchlow, Susan E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AG 221; AGI 5198; AGI 6780; ANTINEOPLASTIC AGENT; AZD 3965; CB 839; ISOCITRATE DEHYDROGENASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTATE DEHYDROGENASE; MONOCARBOXYLATE TRANSPORTER; UNCLASSIFIED DRUG; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL LINE; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GLIOMA; HUMAN; IDH1 GENE; IDH2 GENE; KEAP1 GENE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENERGY METABOLISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84904599432     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.07.001     Document Type: Review

References (65)

1. M.R. Stratton Exploring the genomes of cancer cells: progress and promise Science 331 2011 1553 1558
2. L.A. Garraway, and E.S. Lander Lessons from the cancer genome Cell 153 2013 17 37
3. B.J. Druker, F. Guilhot, and S.G. O'Brien et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417 (Pubitemid 44903745)
4. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 2004
5. P.B. Chapman, A. Hauschild, and C. Robert et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
6. A.T. Shaw, B.Y. Yeap, and B.J. Solomon et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung caner harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
7. P. Workman, B. Al-Lazikani, and P.A. Clarke Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology Curr Opin Pharmacol 13 2013 486 496
8. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
9. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat Rev Cancer 11 2011 85 95
10. L. Galluzzi, O. Kepp, M.G. Vander Heiden, and G. Kroemer Metabolic targets for cancer therapy Nat Rev Drug Discov 12 2013 829 846
11. D.W. Parsons, S. Jones, and X. Zhang et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
12. H. Yan, D.W. Parsons, and G. Jin et al. IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
13. E.R. Mardis, L. Ding, and D.J. Dooling et al. Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 2009 1058 1066
14. L. Dang, D.W. White, and S. Gross et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
15. P.S. Ward, J. Patel, and D.R. Wise et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
16. M.E. Figueroa, O. Abdel-Wahab, and C. Lu et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
17. C. Lu, P.S. Ward, and G.S. Kapoor et al. IDH mutations impair histone demethylation and results in a block to cell differentiation Nature 483 2012 474 478
18. W. Xu, H. Yang, and Y. Liu et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 2011 17 30
19. F. Wang, J. Travins, and B. DeLaBarre et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Science 340 2013 622 626
20. D. Rohle, J. Popovici-Muller, and N. Palaskas et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 2013 626 630
21. J.-A. Losman, R.E. Looper, and P. Koivunen et al. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible Science 339 2013 1621 1625
22. H. Wakimoto, S. Tanaka, W.T. Curry, F. Loebel, D. Zhao, K. Tateishi, J. Chen, L.K. Klofas, N. Lelic, J.C. Kim, and D. Dias-Santagata et al. Targetable signalling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas Clin Cancer Res 20 2014 2898 2909
23. C.V. Dang, A. Le, and P. Gao MYC-induced cancer cell energy metabolism and therapeutic opportunities Clin Cancer Res 15 2009 6479 6483
24. N. Meyer, and L.Z. Penn Reflecting on 25 years with MYC Nat Rev Cancer 8 2008 976 990
25. G. Ott, A. Rosenwald, and E. Campo MYC-driven aggressive B-cell lymphomas: pathogenesis and classification Blood 122 2013 3884 3891
26. H. Beltran The N-Myc oncogene: maximizing its targets, regulation, and therapeutic potential Mol Cancer Res 12 2014 815 822
27. N.M. Sodire, and G.I. Evan Finding cancer's weakest link Oncotarget 2 2011 1307 1313
28. D.M. Miller, S.D. Thomas, A. Islam, D. Muench, and K. Sedoris c-Myc and cancer metabolism Clin Cancer Res 8 2012 5546 5553
29. J.R. Doherty, C. Yang, K.E.N. Scott, M.D. Cameron, M. Fallahi, W. Li, M.A. Hall, A.L. Amelio, J.K. Mishra, and F. Li et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis Cancer Res 74 2014 908 920
30. F. Li, Y. Wang, K.I. Zeller, J.J. Potter, D.R. Wonsey, K.A. O'Donnell, J.-W. Kim, J.T. Yustein, L.A. Lee, and C.V. Dang Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis Mol Cell Biol 25 2005 6225 6234 (Pubitemid 40946570)
31. D.R. Wise, R.J. DeBerardinis, A. Mancuso, N. Sayed, X.-Y. Zhang, H.K. Pfeiffer, I. Nissim, E. Diakhin, M. Yudkoff, S.B. McMahon, and C.B. Thompson Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc Natl Acad Sci U S A 105 2008 18787 19782
32. P. Gao, I. Tchernyshyov, T.-C. Chang, Y.-S. Lee, K. Kita, T. Ochi, K.I. Zeller, A.M. De Marzo, J.E. Van Eyk, J.T. Mendell, and C.V. Dang C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 458 2009 762 766
33. H. Shim, C. Dolde, B.C. Lewis, C.-S. Wu, G. Dang, R.A. Jungmann, R. Dalla-Favera, and C.V. Dang C-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc Natl Acad Sci U S A 94 1997 6658 6663 (Pubitemid 27281920)
34. A. Valera, A. Pujol, X. Gregori, E. Riu, J. Visa, and F. Bosch Evidence from transgenic mice that myc regulates hepatic glycolysis FASEB J 9 1995 1067 1078
35. V.R. Fantin, J. St-Pierre, and P. Leder Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance Cancer Cell 9 2006 425 434 (Pubitemid 43832190)
36. R.A. Ward, C. Brassington, A.L. Breeze, A. Caputo, S. Critchlow, G. Davies, L. Goodwin, G. Hassel, G.A. Holdgate, and M. Mrosek et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation J Med Chem 55 2012 3285 3306
37. A. Kohlmann, S.G. Zech, T. Zhou, R.M. Squillance, L. Commodore, M.T. Greenfield, X. Lu, D.P. Miller, W.S. Huang, and R.M. Thomas et al. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors J Med Chem 56 2013 1023 1040
38. P.S. Dragovich, B.P. Fauber, L.B. Corson, C.Z. Ding, C. Eigenbrot, H. Ge, A.M. Giannetti, T. Hunsaker, and S. Labadie et al. Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase Bioorg Med Chem Lett 23 2013 3186 3194
39. B.P. Fauber, P.S. Dragovich, J. Chen, L.B. Corson, C.Z. Ding, C. Eigenbrot, A.M. Giannetti, T. Hunsaker, S. Labadie, and Y. Liu et al. Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase Bioorg Med Chem Lett 23 2013 5533 5539
40. J. Billiard, J.B. Dennison, J.B. Briand, R.S. Annan, D. Chai, M. Colón, S.A. Gilbert, J. Greshock, J. Jing, and H. Lu et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells Cancer Metab 1 2013 1 17
41. S.K. Parks, J. Chiche, and J. Pouysségur Disrupting proton dynamics and energy metabolism for cancer therapy Nat Rev Cancer 13 2013 611 623
42. M.J. Ovens, A.J. Davie, M.C. Wilson, C.M. Murray, and A.P. Halestrap AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10 Biochem J 425 2010 523 530
43. R. Polanski, C.L. Hodgkinson, A. Fusi, D. Nonaka, L. Priest, P. Kelly, F. Trapani, P.W. Bishop, A. White, and S.E. Critchlow et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer Clin Cancer Res 20 2013 926 937
44. R. Le Floch, J. Chiche, I. Marchiq, T. Naiken, K. Ilc, C.M. Murray, S.E. Critchlow, D. Roux, M.P. Simon, and J. Pouysségur Proc Natl Acad Sci U S A 108 2011 16663 16668
45. M.O. Yuneva, T.W. Fan, T.D. Allen, R.M. Higashi, D.V. Ferraris, T. Tsukamoto, J.M. Matés, F.J. Alonso, C. Wang, and Y. Seo et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type Cell Metab 15 2012 157 170
46. A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto, C.J. Rojas, B.S. Slusher, and H. Zhang et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells Cell Metab 15 2012 110 121
47. B. DeLaBarre, S. Gross, C. Fang, Y. Gao, A. Jha, F. Jiang, J.J. Song, and J.B. Hurov Full-length human glutaminase in complex with an allosteric inhibitor Biochemistry 20 2011 10764 107070
48. M.I. Gross, S.D. Demo, J.B. Dennison, L. Chen, T. Chernov-Rogan, J.R. Janes, G.J. Laidig, E.R. Lewis, J. Li, and A.L. Mackinnon et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer Mol Cancer Ther 13 2014 890 901
49. The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
50. A. Singh, V. Misra, and R.K. Thimmulappa et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med 3 2006 1865 1876 (Pubitemid 44721825)
51. A. Kobayashi, M.I. Kang, and H. Okawa et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Mol Cell Biol 24 2004 7130 7139 (Pubitemid 39014439)
52. T. Ohta, K. Iijima, and M. Miyamoto et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res 68 2008 1303 1309 (Pubitemid 351346836)
53. T. Suzuki, H. Motohashi, and M. Yamamoto Toward clinical application of the Keap1-Nrf2 pathway Trends Pharmacol Sci 34 2013 340 346
54. G.J. Aksoy, U. Dogrusoz, and G. Dresdner et al. Integrative analysis of complex cancer genomics and clinical profiles using cBioPortal Sci Signal 6 2013 1
55. Y. Sato, T. Yoshizato, and Y. Shiraishi et al. Integrated molecular analysis of clear-cell renal cell carcinoma Nat Genet 45 2013 860 867
56. N.J. Yoo, H.R. Kim, and Y.R. Kim et al. Somatic mutations of the KEAP1 gene in common solid cancers Histopathology 60 2012 943 952
57. Y. Mitsuishi, K. Taguchi, and Y. Kawatini et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming Cancer Cell 22 2012 66 79
58. A. Singh, S. Boldin-Adamsky, and R.K. Thimmulappa et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy Cancer Res 68 2008 7975 7984
59. J.D. Hayes, and M. McMahon NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem Sci 34 2009 176 188
60. S. Homma, Y. Ishii, and Y. Morishima et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer Clin Cancer Res 15 2009 3423 3432
61. X. Ma, J. Zhang, and S. Liu et al. Nrf2 knockdown by shRNA inhibits tumour growth and increases efficacy of chemotherapy in cervical cancer Cancer Chemother Pharmacol 69 2012 485 494
62. M.C. Jaramillo, and D.D. Zhang The emerging role of the Nrf2-Keap1 signaling pathway in cancer Genes Dev 27 2013 2179 2191
63. J.K. Watts, and D.R. Corey Silencing disease genes in the laboratory and the clinic J Pathol 226 2012 365 379
64. J.C. Burnett, and J.J. Rossi RNA-based therapeutics: current progress and future prospects Chem Biol 19 2012 60 71
65. H. Dudek, K. Wortham, R. Arvan, A. Shah, B. Ying, W. Cyr, H. Yang, W. Zhou, U. Saxena, Y. Zhou, R. Diwanji, B. Holmes, R. Farkiwala, A. Shah, and B. Brown Dicer substrate siRNAs to MYC, B-catenin, and other target genes effectively induce in vivo target gene knockdown and tumor inhibition AACR Mol Cancer Ther 12 11 Suppl 2013 Abstract nr B222